Reports

Surge in Autoimmune Disorders Among Indians Post-COVID-19: Study Highlights Alarming 30% Rise in Antinuclear Antibody Positivity

The study, which analyzed data from over 1.2 lakh individuals, compared findings from 2019 (before the pandemic) with those from 2022 (post-pandemic).

• By Newsdesk
• New Delhi
• Oct 21, 2024

Reports

Metropolis Healthcare Limited is spearheading efforts to raise awareness about chronic health concerns, focusing on the lingering impacts of COVID-19, especially in relation to autoimmune diseases. A new study, published in the International Journal of Clinical Biochemistry and Research, sheds light on the significant rise in antinuclear antibody (ANA) positivity in India, revealing a 30% increase in cases following COVID-19 infections.

The study, which analyzed data from over 1.2 lakh individuals, compared findings from 2019 (before the pandemic) with those from 2022 (post-pandemic). Results showed a jump in ANA positivity from 39.3% in 2019 to 69.6% in 2022, suggesting a marked shift in how the immune system is functioning in the wake of the virus. This rise indicates that COVID-19 may be influencing the immune system to mistakenly attack the body’s own tissues, potentially leading to the development or worsening of autoimmune conditions.

Antinuclear antibodies are proteins produced when the immune system goes awry, targeting the body's cells instead of foreign invaders. High levels of these antibodies can signal autoimmune diseases like lupus, rheumatoid arthritis, and thyroid disorders, all of which involve symptoms such as inflammation, joint pain, and fatigue. As a result, ANA testing has become a critical tool for healthcare professionals in detecting and managing these disorders.

The findings also indicated that the increase in ANA positivity was consistent across various age groups, with the highest rates observed in individuals aged 31-45, followed by those aged 46-60. Elderly individuals (over 60) maintained high ANA positivity in both periods studied. Additionally, women showed a higher prevalence of ANA positivity compared to men, a trend that persisted from before the pandemic.

The study noted a 9% rise in the nuclear homogeneous pattern, which is commonly associated with systemic lupus erythematosus (SLE) and rheumatoid arthritis. This increase underscores the need for heightened vigilance in diagnosing these specific conditions post-COVID.

Dr. Alap Christy, Vice President & Scientific Business Head at Metropolis Healthcare, emphasized the study’s significance: "The surge in ANA positivity post-COVID reflects the immune system's heightened activity against the virus, which in some instances causes the body to attack itself. This has led to an observable increase in autoimmune conditions since the pandemic, highlighting the need for early detection, particularly among women and older adults."

Dr. Kirti Chadha, Chief Science and Innovation Officer at Metropolis, added, "The pandemic has had far-reaching effects beyond the immediate illness, as evidenced by the rise in autoimmune disorders. This presents an opportunity to enhance diagnostic approaches, enabling more effective management of health conditions through early identification."

The ANA test, regarded as a gold standard for autoimmune disease screening, is often followed by more specific diagnostic tests like ELISA and ImmunoBlot to confirm the condition and pinpoint the exact autoimmune disorder.

As healthcare systems worldwide continue to address the enduring effects of COVID-19, Metropolis Healthcare encourages regular health screenings and proactive lifestyle choices. Maintaining a balanced diet, exercising, managing stress, and getting sufficient sleep are essential measures to support immune health and reduce the risk of autoimmune diseases.